Search results

770 results

Sorted by Relevance . Sort by Date

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
NICE guidelines Remove NICE guidelines filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Cancer service guidelines Remove Cancer service guidelines filter

Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]

Proposed [GID-HST10034] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
VTS-270 for treating Niemann-Pick type C1 (ID1267)

Proposed [GID-HST10020] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

Proposed [GID-HST10019] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Proposed [GID-HST10022] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

Proposed [GID-HST10039] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Avalglucosidase alfa for treating Pompe disease [ID3737]

Proposed [GID-HST10030] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

Proposed [GID-HST10037] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Lenti-D for treating cerebral adrenoleukodystrophy [ID1284]

Proposed [GID-HST10038] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818

Proposed [GID-HST10040] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

In development [GID-HST10032] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

In development [GID-HST10033] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]

In development [GID-HST10026] Expected publication date: 25 March 2021

Type

Highly specialised technologies guidance

Status

In development
Metreleptin for treating lipodystrophy (ID861)

In development [GID-HST10011] Expected publication date: 24 February 2021

Type

Highly specialised technologies guidance

Status

In development
OTL-200 for treating metachromatic leukodystrophy [ID1666]

In development [GID-HST10028] Expected publication date: 13 August 2021

Type

Highly specialised technologies guidance

Status

In development
Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]

In development [GID-HST10027] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Givosiran for treating acute hepatic porphyria [ID1549]

In development [GID-HST10035] Expected publication date: 04 August 2021

Type

Highly specialised technologies guidance

Status

In development
Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 02 March 2021

Type

Antimicrobial prescribing guideline

Status

In development
Tobacco: preventing uptake, promoting quitting and treating dependence (update)

In development [GID-NG10086] Expected publication date: 01 September 2021

Type

NICE guideline

Status

In development
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]

In development [GID-TA10587] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]

In development [GID-TA10472] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]

Proposed [GID-TA10667] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]

Proposed [GID-TA10599] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

Proposed [GID-TA10604] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

Proposed [GID-TA10668] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

Proposed [GID-TA10637] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

Proposed [GID-TA10638] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tocilizumab for treating systemic sclerosis (ID1396)

Proposed [GID-TA10346] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Icosapent ethyl for reducing the risk of cardiovascular events due to hypertriglyceridemia [ID3831]

Proposed [GID-TA10736] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]

Proposed [GID-TA10753] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remdesivir for treating COVID-19 [ID3808]

Proposed [GID-TA10721] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Bupivacaine–meloxicam for treating postoperative pain [ID2728]

Proposed [GID-TA10716] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mepolizumab for treating hypereosinophilic syndrome [ID3749]

Proposed [GID-TA10755] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]

Proposed [GID-TA10654] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]

Proposed [GID-TA10714] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]

Proposed [GID-TA10727] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

Proposed [GID-TA10728] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amivantamab for non-small cell lung cancer [ID3836]

Proposed [GID-TA10729] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]

Proposed [GID-TA10730] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

Proposed [GID-TA10700] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]

Proposed [GID-TA10658] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

Proposed
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

Proposed [GID-TA10536] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

Proposed [GID-TA10757] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]

Proposed [GID-TA10758] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]

Proposed [GID-TA10706] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed